Neoadjuvant therapy in Hormone Receptor-Positive/HER2-Negative Breast Cancer

Breast cancer is a leading cause of mortality and morbidity worldwide. In countries where early detection programs are implemented, approximately 90-95% of patients with breast cancer (BC) present with localized disease[1]. Hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC, defined by the immunohistochemical expression of oestrogen (ER) and/or progesterone (PR) receptor, represents the most common subtype, encompassing at least two-thirds of all new diagnoses [2-4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research